temozolomide
temozolomide: 88 clinical trials tracked.
temozolomide evidence translation
What we can confirm
88 tracked trials
What it means
What to watch
Prepared research question
What is verified about temozolomide, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 9 study sponsors
Related indications
Clinical Trial Registry Records (88)showing 10 most recent
A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Primary endpoint: Median overall survival (OS)
PH Weighted Chemical Exchange Saturation Transfer Based Surgical Resections of Glioblastoma
Primary endpoint: Progression free survival
Phase 1/2 Trial of PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II)
Primary endpoint: Proportion of patients with unacceptable toxicity
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion
Primary endpoint: Part 1: Number of participants who achieve Objective Response (OR)
Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas
Primary endpoint: Progression free survival (PFS) by blinded independent central review (BICR)
A Randomized Phase III Study Comparing Temporally-Modulated Pulsed Radiation Therapy (TMPRT) Versus Standard Radiation Therapy With Temozolomide for Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma
Primary endpoint: Neurocognitive function (NCF)
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma
Primary endpoint: Progression Free Survival (PFS)
Mycophenolate Mofetil to Overcome Glioblastoma Resistance to Radiotherapy and Temozolomide
Primary endpoint: Progression free survival (PFS) (phase II)
A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter and EGFRvIII
Primary endpoint: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR)
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Primary endpoint: Feasibility and Safety - Consolidation